Nakamura and coworkers [40] exploited a pseudo-receptor system in which viruses could be retargeted to tumor-selective CD38, epidermal growth factor receptor (EGFR), or mutant EGFR VIII (EGFR VIII) after disabling the standard targeting receptors to efficiently enter CD46- and SLAM-positive cells in vivo. This evidence concerns the gene CD46 and neoplasm.